Insititute Gustave Roussy Implements Vela Diagnostics Sentosa Next Generation Sequencing System in Routine Diagnostics

HAMBURG, Germany, November 24, 2015 /PRNewswire/ --

After successful evaluation, Gustave Roussy, the leading Comprehensive Cancer Centre in Europe, is starting to use the Vela Next Generation Sequencing System for diagnosing mutations relevant to colorectal cancer, non small cell lung cancer and melanoma in routine diagnostics. The Sentosa system launched in 2014 was the first CE-IVD system on the market, which combined a complete solution from sample to result with reagents, consumables, assays, instruments and informatics including reporting and sample tracking capability. The Sentosa system provides an automated workflow for extraction, library and template preparation as well as data analysis. The clinically relevant targets are sequenced and a diagnostic report including quality scores is provided.

The Vela system constitutes an attractive fully automated CE-IVD solution to perform somatic molecular analysis based on formalin fixed tissue. During evaluation the systems provides efficient results corresponding to criteria for molecular testing for daily analysis.  

We are very happy to work with a prestigious institute such as Gustave Roussy said Dr. Andreas Görtz, Managing Director Vela Diagnostics Europe. Moving forward Vela will have a number of collaborations for solid and liquid tumour diagnostics with Gustave Roussy using its complete next generation sequencing solution with routine diagnostics features such as automation, low turn around time and clinical relevance. Our system was developed with the routine laboratory in mind. Testing requires minimal sample input, space and hands on time.  Panels combine targets oncologists require for clinical decision making said Andreas Görtz.  Moving forward additional tests for leukaemia and infectious disease diagnostics will be launched.

Press contact:
Mark Hünken
mark.huenken@veladx.com
+49(0)40-890-662232